In a new commentary for Pharmaceutical Market Europe, Precision for Value’s Austin Speier, VP, Emerging Technology, examines the promise and advantages of integrating digital biomarkers into precision medicine. (more…)

In an in-depth commentary for Pharmaceutical Market Europe, senior economist Jason Shafrin argues for real-world evidence (RWE) to become the “gold standard” of scientific evidence and heath technology assessments. (more…)

Chief Medical Officer Gerry Messerschmidt authors a new commentary in Biocompare outlining critical success factors toward cancer vaccine development. (more…)

Rare Disease Report interviews Chief Medical Officer Gerald Messerschmidt while at the American Society of Hematology Annual Meeting. (more…)

Precisioneffect Chief Creative Officer Deborah Lotterman pens a new commentary in the latest edition of MedAd News, “Making Sense of the Irrational.” (more…)

Senior Vice President Jeremy Schafer and Chief Creative Officer Deborah Lotterman submit a new commentary to MedAd News,“Enriching the Patient Journey: When Cost Creates Side Effects.” (more…)

In the latest edition of Managed Care, Precision for Value Payer Strategy Team members Ami Gopalan and Jeremy Schafer take a look at some of the cost-sharing strategies being employed by PBMs and ask the question, What latent effects might these programs have? (more…)

In the latest edition of Clinical Leader, Precision for Value’s Dominic Galante addresses how real-world evidence is being leveraged after the adoption of the 21st Century Cures Act, and provides some next steps for life science companies.  (more…)

In the current edition of Managed Healthcare Executive, Precision Oncology’s chief medical officer Dr. Gerry Messerschmidt comments on the unprecedented pace of outcomes improvements. (more…)

In a new article for Drug Discovery & Development, Precision Health Economics senior research economist Jason Shafrin addresses the use of real-world evidence, why we need it and how to effectively implement it. (more…)